Inovio COVID-19 vaccine

Inovio COVID-19 vaccine
Vaccine description
Target	SARS-CoV-2
Vaccine type	DNA
Clinical data
Other names	INO-4800
Routes of; administration	Intradermal
Identifiers
DrugBank	DB15693;

Inovio COVID-19 vaccine is a COVID-19 vaccine candidate developed by Inovio Pharmaceuticals.

History[]

In February 2020 after receiving details of the genetic sequence of the coronavirus, Inovio announced that it had produced a preclinical DNA-based vaccine as a potential therapy for COVID-19.^[1]^[2] Inovio is in competition to develop a coronavirus vaccine with numerous other companies, which were conducting preclinical or early-stage human research on more than 170 vaccine candidates, as of late June.^[3] In April 2020, Inovio began a Phase I trial of the COVID-19 vaccine candidate, INO-4800.^[4]

Clinical trials[]

Inovio is collaborating with Beijing Advaccine Biotechnology Co., a Chinese biotech firm,^[2] in order to speed its acceptance by regulatory authorities in China, with plans to begin human clinical trials of a candidate vaccine in China during the first half of 2020.^[5]^[6] Inovio has partnerships with manufacturers to scale up production of a vaccine if preliminary efficacy trials are successful.^[2] In April 2020, the company began human Phase I safety studies of its lead vaccine (INO-4800) in the United States, and a Phase I-II trial in South Korea, to test for immunization against the COVID-19 virus.^[5]^[7]

In early June, Inovio partnered with the International Vaccine Institute and Seoul National University, South Korea, to advance human research on INO-4800 in a Phase I-II safety and efficacy trial to be conducted on 120 participants at Seoul National University Hospital beginning in June.^[8] The trial is funded by the Coalition for Epidemic Preparedness Innovations and supported by the Korea Centers for Disease Control and Prevention and the Korea National Institute of Health.^[8]

On April 23, 2021 Inovio said the U.S. Department of Defense discontinued funding for the phase III portion of an ongoing trial of its COVID-19 vaccine candidate, INO-4800, in light of the broad availability of other COVID-19 vaccines in the U.S. The news followed recent phase I data showing '4800 performed about in line with already available competitors against the existing SARS-CoV-2 variants. https://www.bioworld.com/articles/506316-inovio-shares-sink-as-dod-pulls-support-for-phase-iii-portion-of-covid-19-vaccine-study?v=preview NOVIO's global Phase 3 efficacy trial receives authorization to proceed from Brazil; other countries to follow

On August 26, 2021 Inovio's global Phase 3 efficacy trial receives authorization to proceed from Brazil https://ir.inovio.com/news-releases/news-releases-details/2021/INOVIO-Receives-Authorization-to-Conduct-Phase-3-Efficacy-Trial-of-its-COVID-19-DNA-Vaccine-Candidate-INO-4800/default.aspx

On October 26, 2021 The World Health Organization launched a Global Covid-19 Trial termed as the Solidarity Trial Vaccines. Inovio INO-4800 was chosen as the first DNA Vaccine to be introduced in the largest vaccine trial in history. The Countries of Colombia, Mali and the Philippines announced participation with many other countries yet to be named. The WHO is directly financing this trial. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-of-covid-19-vaccines

On December 14, 2021 Inovio released Clinical Data on Phase 1 and 2 trials held in the USA. The Data showed zero Level 3 Adverse Events. Conclusion INO-4800 appears safe and tolerable as a primary series and as a booster with the induction of both humoral and cellular immune responses. In addition to eliciting neutralizing antibodies, INO-4800 also induced T cell immune responses as demonstrated by IFNγ ELISpot. Finally, as a homologous booster, INO-4800, when administered 6-10.5 months following the primary series, resulted in an increased immune response without increase in reactogenicity. https://www.researchgate.net/publication/356795013_571_Safety_and_Immunogenicity_of_INO-4800_a_COVID-19_DNA_Vaccine_as_a_Primary_Series_and_Booster

References[]

^ Linnane C (8 March 2020). "Inovio shares rally after biotech says human trials of coronavirus vaccine will start in April". MarketWatch. Retrieved 8 March 2020.
^ ^a ^b ^c Freeman M. "Is a vaccine for the coronavirus coming? Inovio says it has designed one in San Diego". Los Angeles Times. Retrieved 17 February 2020.
^ "COVID-19 vaccine tracker (Select vaccine tab)". Milken Institute. 22 June 2020. Retrieved 23 June 2020. Lay summary. {{cite web}}: Cite uses deprecated parameter |lay-url= (help)
^ Clinical trial number NCT04336410 for "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers" at ClinicalTrials.gov
^ ^a ^b Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S (May 2020). "The COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. PMID 32273591.
^ Mazumdar T (30 January 2020). "Coronavirus: Scientists race to develop a vaccine". BBC News – Health. Retrieved 3 February 2020.
^ "IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea". International Vaccine Institute. 16 April 2020. Retrieved 23 April 2020.
^ ^a ^b "IVI and SNU partner to trial Inovio Covid-19 vaccine in Korea". Clinical Trials Arena. 5 June 2020. Retrieved 8 June 2020.

External links[]

Scholia has a profile for INO-4800 (Q96695266).

[mw3-08-1] Linnane C (8 March 2020). "Inovio shares rally after biotech says human trials of coronavirus vaccine will start in April". MarketWatch. Retrieved 8 March 2020.

[freeman-2] Freeman M. "Is a vaccine for the coronavirus coming? Inovio says it has designed one in San Diego". Los Angeles Times. Retrieved 17 February 2020.

[milken-3] "COVID-19 vaccine tracker (Select vaccine tab)". Milken Institute. 22 June 2020. Retrieved 23 June 2020. Lay summary. {{cite web}}: Cite uses deprecated parameter |lay-url= (help)

[Inov-04336410-4] Clinical trial number NCT04336410 for "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers" at ClinicalTrials.gov

[thanh-5] Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S (May 2020). "The COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. PMID 32273591.

[6] Mazumdar T (30 January 2020). "Coronavirus: Scientists race to develop a vaccine". BBC News – Health. Retrieved 3 February 2020.

[7] "IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea". International Vaccine Institute. 16 April 2020. Retrieved 23 April 2020.

[cta-8] "IVI and SNU partner to trial Inovio Covid-19 vaccine in Korea". Clinical Trials Arena. 5 June 2020. Retrieved 8 June 2020.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

COVID-19 pandemic
Part of a series on the

COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Evacuations Face masks International aid Investigations into origin Lockdowns by country Misinformation by governments China US Fake treatments Protests US Software Travel restrictions United Nations World Health Organization WTO IP waiver Undercounting of deaths Zero-COVID National responses Africa China European Union Germany Ghana India New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Vaccine candidates CoronaVac Covaxin Convidecia Janssen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Canadian meat US meat Food security Journalism Music Performing arts Retail Shipping Sports Ireland Philippines Television US programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US
Impacts Animals Black people Crime Ireland Death rates by country Disability Domestic violence Emergency evacuations Education Female Ghana Ireland UK US Environment Hospitals Language LGBT community Long-term care Mental health Symptoms Migration Military Notable deaths South Africa Other health issues Politics Ireland Malaysia Russia Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Society Ireland Malaysia New Zealand Russia UK US Strikes Suicides Telehealth Xenophobia and racism
COVID-19 portal
v t